CanSino Biologics Inc.

  • CanSino BIO Viral Vaccine Manufacturing site in Tianjin, China
About CanSino Biologics Inc.

Incorporated in 2009, CanSinoBIO (SSE: 688185, HKEX: 06185) commits to providing high-quality, innovative, and affordable vaccines for global public health security. It possesses five integrated platform technologies upon which the company has established a rich portfolio of a pipeline products preventing more than 10 diseases, including Ad5-EBOV Ebola vaccine, Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) Menhycia®, Group A and Group C Meningococcal Conjugate Vaccine (CRM197) Menphecia®, inhaled COVID-19 vaccine Convidecia Air®.

  • CN
  • 2024
    On CPHI since
  • 1
    Certificates
  • 1000 - 4999
    Employees
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Technology
Contact info

Products from CanSino Biologics Inc. (5)